The purpose of this project is to examine the effects of mu-opiate antagonism on the rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
6
Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
Placebo
VA Connecticut Healthcare System
West Haven, Connecticut, United States
Behavioral Measures
Subjective effects and perceptual alterations will be assessed using the Positive and Negative Symptom Subscale (PANNS).
Time frame: 4 test days
Visual analog scales
Will assess subjective effects, perceptual alterations, and cognitive effects.
Time frame: 4 test days
Clinician Administered Dissociative States Scales (CADSS)
Will measure subjective effects, perceptual alterations, and cognitive effects.
Time frame: 4 test days
Psychotomimetic States Inventory (PSI)
Will assess subjective effects, perceptual alterations, and cognitive effects.
Time frame: 4 test days
Marijuana Withdrawal Scale
Will assess subjective effects, perceptual alterations, and cognitive effects.
Time frame: 4 test days
Clinical Opiate Withdrawal Scale
Will assess subjective effects, perceptual alterations, and cognitive effects.
Time frame: 4 test days
Marijuana Craving Scale
Will assess subjective effects, perceptual alterations, and cognitive effects.
Time frame: 4 test days
Neuro cognitive battery
Will assess cognitive effects.
Time frame: 4 test days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.